Kevin Deane
Concepts (475)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 127 | 2026 | 1184 | 18.680 |
Why?
| | Autoantibodies | 69 | 2026 | 1498 | 7.730 |
Why?
| | Anti-Citrullinated Protein Antibodies | 32 | 2026 | 129 | 6.850 |
Why?
| | Rheumatoid Factor | 42 | 2026 | 177 | 5.430 |
Why?
| | Peptides, Cyclic | 32 | 2026 | 276 | 3.510 |
Why?
| | Antirheumatic Agents | 13 | 2026 | 309 | 3.180 |
Why?
| | Autoimmunity | 23 | 2025 | 924 | 3.030 |
Why?
| | Malaria | 4 | 2026 | 73 | 2.620 |
Why?
| | Sputum | 5 | 2025 | 302 | 1.600 |
Why?
| | Rheumatic Diseases | 4 | 2022 | 101 | 1.570 |
Why?
| | Social Determinants of Health | 3 | 2026 | 315 | 1.530 |
Why?
| | Methotrexate | 5 | 2025 | 234 | 1.460 |
Why?
| | Lung Diseases, Interstitial | 11 | 2025 | 677 | 1.290 |
Why?
| | Hydroxychloroquine | 3 | 2026 | 65 | 1.250 |
Why?
| | Humans | 166 | 2026 | 145625 | 1.220 |
Why?
| | Disease Progression | 22 | 2026 | 2857 | 1.160 |
Why?
| | Biomarkers | 32 | 2026 | 4329 | 1.150 |
Why?
| | Immunoglobulin A | 11 | 2023 | 205 | 1.090 |
Why?
| | Arthralgia | 4 | 2025 | 61 | 1.080 |
Why?
| | Autoimmune Diseases | 5 | 2024 | 466 | 1.040 |
Why?
| | HIV Infections | 5 | 2023 | 3210 | 1.000 |
Why?
| | Autoantigens | 8 | 2023 | 426 | 0.940 |
Why?
| | Middle Aged | 79 | 2026 | 36359 | 0.900 |
Why?
| | Female | 103 | 2026 | 79080 | 0.880 |
Why?
| | Male | 90 | 2026 | 73014 | 0.880 |
Why?
| | Inflammation | 11 | 2025 | 2915 | 0.840 |
Why?
| | Bronchial Diseases | 3 | 2013 | 38 | 0.820 |
Why?
| | Early Medical Intervention | 2 | 2014 | 59 | 0.820 |
Why?
| | Risk Factors | 36 | 2026 | 10840 | 0.800 |
Why?
| | Extracellular Traps | 3 | 2021 | 54 | 0.790 |
Why?
| | Genetic Predisposition to Disease | 16 | 2023 | 2455 | 0.770 |
Why?
| | Poverty | 2 | 2026 | 530 | 0.760 |
Why?
| | Rheumatology | 7 | 2025 | 136 | 0.750 |
Why?
| | Adult | 63 | 2026 | 40821 | 0.740 |
Why?
| | Mucous Membrane | 2 | 2024 | 129 | 0.720 |
Why?
| | Early Diagnosis | 8 | 2022 | 249 | 0.710 |
Why?
| | Lung Diseases | 4 | 2022 | 787 | 0.710 |
Why?
| | Mosquito Vectors | 1 | 2022 | 32 | 0.690 |
Why?
| | Insecticides | 1 | 2022 | 44 | 0.690 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2023 | 237 | 0.680 |
Why?
| | Lupus Erythematosus, Systemic | 4 | 2022 | 240 | 0.680 |
Why?
| | Case-Control Studies | 19 | 2025 | 3633 | 0.670 |
Why?
| | Joints | 4 | 2015 | 107 | 0.660 |
Why?
| | Precision Medicine | 3 | 2020 | 462 | 0.650 |
Why?
| | Prodromal Symptoms | 1 | 2020 | 20 | 0.650 |
Why?
| | B-Lymphocytes | 5 | 2026 | 884 | 0.630 |
Why?
| | Epitopes | 8 | 2023 | 479 | 0.630 |
Why?
| | Aged | 45 | 2026 | 26251 | 0.610 |
Why?
| | Qualitative Research | 6 | 2025 | 1720 | 0.580 |
Why?
| | Citrullination | 2 | 2020 | 12 | 0.580 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2023 | 845 | 0.580 |
Why?
| | Histones | 4 | 2023 | 670 | 0.570 |
Why?
| | Lung | 7 | 2020 | 4119 | 0.560 |
Why?
| | Sexual and Gender Minorities | 1 | 2023 | 268 | 0.560 |
Why?
| | Asymptomatic Diseases | 2 | 2021 | 102 | 0.520 |
Why?
| | Uganda | 3 | 2026 | 91 | 0.510 |
Why?
| | Immunoglobulin G | 11 | 2023 | 899 | 0.510 |
Why?
| | Synovial Membrane | 5 | 2026 | 130 | 0.510 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2020 | 272 | 0.500 |
Why?
| | Pedigree | 2 | 2020 | 507 | 0.500 |
Why?
| | Transgender Persons | 1 | 2020 | 213 | 0.490 |
Why?
| | Citrulline | 2 | 2016 | 45 | 0.490 |
Why?
| | Focus Groups | 4 | 2025 | 587 | 0.480 |
Why?
| | Synovitis | 2 | 2023 | 35 | 0.480 |
Why?
| | Antibodies, Anti-Idiotypic | 2 | 2015 | 50 | 0.480 |
Why?
| | Human Migration | 1 | 2016 | 26 | 0.470 |
Why?
| | Transients and Migrants | 1 | 2016 | 28 | 0.470 |
Why?
| | Rituximab | 3 | 2025 | 208 | 0.460 |
Why?
| | Arthritis | 2 | 2016 | 97 | 0.460 |
Why?
| | Prospective Studies | 22 | 2025 | 8087 | 0.440 |
Why?
| | Immunoglobulin M | 7 | 2023 | 284 | 0.440 |
Why?
| | Th17 Cells | 3 | 2025 | 103 | 0.430 |
Why?
| | Abatacept | 2 | 2025 | 56 | 0.420 |
Why?
| | Cytokines | 10 | 2023 | 2079 | 0.410 |
Why?
| | Sexual Behavior | 2 | 2016 | 489 | 0.410 |
Why?
| | Antipsychotic Agents | 1 | 2016 | 178 | 0.410 |
Why?
| | Pneumonia | 1 | 2020 | 633 | 0.400 |
Why?
| | Family | 7 | 2021 | 680 | 0.400 |
Why?
| | Patient Acceptance of Health Care | 1 | 2020 | 880 | 0.390 |
Why?
| | Psychotic Disorders | 1 | 2016 | 181 | 0.390 |
Why?
| | Risk-Taking | 1 | 2016 | 321 | 0.390 |
Why?
| | Chemokines | 2 | 2012 | 217 | 0.390 |
Why?
| | Endothelium, Vascular | 4 | 2013 | 952 | 0.380 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 2013 | 47 | 0.380 |
Why?
| | Risk Reduction Behavior | 1 | 2014 | 219 | 0.370 |
Why?
| | Tanzania | 3 | 2021 | 74 | 0.360 |
Why?
| | Risk Assessment | 9 | 2025 | 3678 | 0.360 |
Why?
| | Hazardous Substances | 1 | 2012 | 16 | 0.360 |
Why?
| | Cross-Sectional Studies | 11 | 2026 | 5875 | 0.360 |
Why?
| | Observational Studies as Topic | 2 | 2024 | 133 | 0.360 |
Why?
| | Lymphocyte Activation | 2 | 2026 | 1136 | 0.350 |
Why?
| | Mass Screening | 4 | 2025 | 1300 | 0.340 |
Why?
| | Susac Syndrome | 1 | 2011 | 3 | 0.340 |
Why?
| | Smoking | 9 | 2024 | 1478 | 0.330 |
Why?
| | Fatty Acids, Omega-3 | 3 | 2017 | 145 | 0.330 |
Why?
| | Cellular Senescence | 2 | 2026 | 225 | 0.330 |
Why?
| | Gene-Environment Interaction | 1 | 2012 | 188 | 0.320 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2011 | 83 | 0.320 |
Why?
| | Malondialdehyde | 2 | 2020 | 31 | 0.310 |
Why?
| | Acetaldehyde | 2 | 2020 | 17 | 0.310 |
Why?
| | Mucin-5B | 3 | 2025 | 234 | 0.310 |
Why?
| | Protein Processing, Post-Translational | 1 | 2013 | 485 | 0.310 |
Why?
| | Health Fairs | 1 | 2009 | 10 | 0.310 |
Why?
| | Antibodies, Antinuclear | 5 | 2023 | 60 | 0.310 |
Why?
| | Research Design | 3 | 2024 | 1139 | 0.300 |
Why?
| | Emigration and Immigration | 1 | 2010 | 66 | 0.300 |
Why?
| | Postmenopause | 7 | 2023 | 394 | 0.300 |
Why?
| | Incidence | 10 | 2026 | 2910 | 0.300 |
Why?
| | Social Stigma | 2 | 2023 | 174 | 0.300 |
Why?
| | Glucocorticoids | 3 | 2021 | 536 | 0.280 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2025 | 1223 | 0.280 |
Why?
| | Antibodies, Bacterial | 3 | 2023 | 147 | 0.280 |
Why?
| | Clinical Trials as Topic | 2 | 2025 | 1062 | 0.270 |
Why?
| | Young Adult | 11 | 2026 | 14240 | 0.250 |
Why?
| | B-Cell Activating Factor | 2 | 2024 | 21 | 0.250 |
Why?
| | Interviews as Topic | 3 | 2025 | 926 | 0.250 |
Why?
| | Health Behavior | 3 | 2018 | 801 | 0.250 |
Why?
| | Animals | 12 | 2025 | 38030 | 0.240 |
Why?
| | Chlamydia trachomatis | 2 | 2025 | 49 | 0.240 |
Why?
| | Antibody Formation | 4 | 2023 | 290 | 0.240 |
Why?
| | Immunophenotyping | 2 | 2025 | 324 | 0.240 |
Why?
| | Antibodies, Antiphospholipid | 1 | 2005 | 29 | 0.230 |
Why?
| | Chlamydia Infections | 2 | 2025 | 79 | 0.220 |
Why?
| | Qa-SNARE Proteins | 1 | 2025 | 18 | 0.220 |
Why?
| | Developing Countries | 2 | 2025 | 312 | 0.220 |
Why?
| | Vasculitis | 1 | 2005 | 69 | 0.220 |
Why?
| | HLA-B27 Antigen | 1 | 2024 | 16 | 0.220 |
Why?
| | Arthritis, Psoriatic | 1 | 2024 | 15 | 0.210 |
Why?
| | Complement Factor H | 1 | 2025 | 81 | 0.210 |
Why?
| | Complement Activation | 2 | 2025 | 412 | 0.200 |
Why?
| | Longitudinal Studies | 5 | 2025 | 3005 | 0.200 |
Why?
| | Spondylarthritis | 1 | 2024 | 50 | 0.200 |
Why?
| | Prevalence | 5 | 2025 | 2852 | 0.200 |
Why?
| | Likelihood Functions | 1 | 2024 | 138 | 0.200 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2024 | 76 | 0.200 |
Why?
| | Polysaccharides | 2 | 2017 | 88 | 0.200 |
Why?
| | Risk | 3 | 2016 | 917 | 0.200 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2024 | 127 | 0.200 |
Why?
| | C-Reactive Protein | 7 | 2025 | 427 | 0.190 |
Why?
| | Estrogens | 3 | 2017 | 364 | 0.190 |
Why?
| | London | 1 | 2023 | 46 | 0.190 |
Why?
| | HLA-DR Antigens | 1 | 2024 | 211 | 0.190 |
Why?
| | Clinical Decision-Making | 2 | 2024 | 364 | 0.190 |
Why?
| | Africa South of the Sahara | 1 | 2023 | 56 | 0.190 |
Why?
| | Down-Regulation | 1 | 2025 | 612 | 0.190 |
Why?
| | Protein-Arginine Deiminases | 3 | 2021 | 16 | 0.190 |
Why?
| | Autophagy | 1 | 2025 | 290 | 0.190 |
Why?
| | Mouth Mucosa | 3 | 2023 | 84 | 0.180 |
Why?
| | Time Factors | 6 | 2019 | 7079 | 0.180 |
Why?
| | Immunoglobulin Isotypes | 1 | 2022 | 36 | 0.180 |
Why?
| | Transforming Growth Factor beta | 1 | 2025 | 466 | 0.180 |
Why?
| | Trichloroethylene | 1 | 2022 | 8 | 0.180 |
Why?
| | Patient Education as Topic | 3 | 2018 | 769 | 0.180 |
Why?
| | Periodontal Diseases | 1 | 2023 | 62 | 0.180 |
Why?
| | Insecticide-Treated Bednets | 1 | 2022 | 7 | 0.180 |
Why?
| | Gender Identity | 1 | 2023 | 132 | 0.180 |
Why?
| | Policy | 1 | 2023 | 147 | 0.180 |
Why?
| | Women's Health | 5 | 2017 | 317 | 0.170 |
Why?
| | Blood Platelets | 1 | 2025 | 380 | 0.170 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2025 | 1148 | 0.170 |
Why?
| | Biological Products | 2 | 2022 | 257 | 0.170 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2025 | 929 | 0.170 |
Why?
| | Leukocytes, Mononuclear | 3 | 2024 | 585 | 0.170 |
Why?
| | Homosexuality, Male | 1 | 2023 | 231 | 0.170 |
Why?
| | Pulmonary Fibrosis | 1 | 2025 | 395 | 0.170 |
Why?
| | Organ Specificity | 2 | 2019 | 306 | 0.170 |
Why?
| | Sex Factors | 5 | 2020 | 2101 | 0.170 |
Why?
| | Double-Blind Method | 1 | 2026 | 2064 | 0.160 |
Why?
| | Housing | 1 | 2022 | 141 | 0.160 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2021 | 97 | 0.160 |
Why?
| | Neutrophil Activation | 1 | 2021 | 84 | 0.160 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 102 | 0.160 |
Why?
| | Sarcoidosis | 1 | 2022 | 164 | 0.160 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 15 | 1 | 2020 | 8 | 0.160 |
Why?
| | Chemokine CXCL16 | 1 | 2020 | 4 | 0.160 |
Why?
| | Hemorrhage | 1 | 2005 | 824 | 0.160 |
Why?
| | Museums | 1 | 2000 | 9 | 0.150 |
Why?
| | Intestines | 2 | 2021 | 351 | 0.150 |
Why?
| | Sjogren's Syndrome | 1 | 2020 | 31 | 0.150 |
Why?
| | Severity of Illness Index | 8 | 2022 | 2910 | 0.150 |
Why?
| | Muramidase | 1 | 2020 | 66 | 0.150 |
Why?
| | T-Lymphocytes | 2 | 2025 | 2007 | 0.150 |
Why?
| | Cytomegalovirus Infections | 1 | 2022 | 203 | 0.150 |
Why?
| | Public-Private Sector Partnerships | 1 | 2020 | 44 | 0.150 |
Why?
| | Pandemics | 2 | 2025 | 1700 | 0.150 |
Why?
| | Art Therapy | 1 | 2000 | 23 | 0.150 |
Why?
| | Complement System Proteins | 2 | 2022 | 324 | 0.150 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 193 | 0.150 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2020 | 88 | 0.150 |
Why?
| | Attitude | 1 | 2021 | 253 | 0.150 |
Why?
| | United Kingdom | 1 | 2020 | 376 | 0.150 |
Why?
| | Bacteriophages | 1 | 2021 | 110 | 0.150 |
Why?
| | Age Factors | 7 | 2020 | 3321 | 0.140 |
Why?
| | Nuclear Family | 1 | 2019 | 50 | 0.140 |
Why?
| | Inflammation Mediators | 2 | 2020 | 507 | 0.140 |
Why?
| | Retrospective Studies | 5 | 2024 | 17291 | 0.140 |
Why?
| | Multiple Sclerosis | 1 | 2024 | 434 | 0.140 |
Why?
| | Gene Expression | 2 | 2022 | 1461 | 0.140 |
Why?
| | Gain of Function Mutation | 1 | 2018 | 35 | 0.140 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2016 | 48 | 0.140 |
Why?
| | Arthritis, Experimental | 1 | 2020 | 142 | 0.140 |
Why?
| | Dexamethasone | 1 | 2020 | 368 | 0.140 |
Why?
| | Socioeconomic Factors | 4 | 2025 | 1323 | 0.140 |
Why?
| | Mitochondria | 2 | 2025 | 996 | 0.140 |
Why?
| | Occupational Exposure | 1 | 2022 | 356 | 0.140 |
Why?
| | Proteomics | 1 | 2025 | 1202 | 0.130 |
Why?
| | Monocytes | 1 | 2020 | 538 | 0.130 |
Why?
| | United States | 9 | 2025 | 16041 | 0.130 |
Why?
| | HLA-DR4 Antigen | 3 | 2007 | 74 | 0.130 |
Why?
| | Vascular Stiffness | 2 | 2013 | 488 | 0.130 |
Why?
| | Cohort Studies | 10 | 2022 | 6045 | 0.130 |
Why?
| | Remission Induction | 2 | 2021 | 308 | 0.130 |
Why?
| | Galactose | 1 | 2017 | 34 | 0.120 |
Why?
| | Metabolome | 1 | 2020 | 390 | 0.120 |
Why?
| | Health Services Accessibility | 1 | 2025 | 1101 | 0.120 |
Why?
| | Global Health | 1 | 2020 | 402 | 0.120 |
Why?
| | Coronary Disease | 2 | 2017 | 380 | 0.120 |
Why?
| | Seroepidemiologic Studies | 3 | 2014 | 169 | 0.120 |
Why?
| | Glycosylation | 1 | 2017 | 175 | 0.120 |
Why?
| | Adiponectin | 1 | 2018 | 243 | 0.120 |
Why?
| | Hydrolases | 2 | 2021 | 42 | 0.120 |
Why?
| | Decision Making | 1 | 2024 | 987 | 0.120 |
Why?
| | Sex Work | 1 | 2016 | 23 | 0.120 |
Why?
| | Military Personnel | 2 | 2021 | 715 | 0.120 |
Why?
| | Plasma Cells | 1 | 2016 | 80 | 0.120 |
Why?
| | Tomography, X-Ray Computed | 5 | 2025 | 2766 | 0.120 |
Why?
| | Estradiol | 3 | 2017 | 517 | 0.120 |
Why?
| | HLA Antigens | 1 | 2017 | 241 | 0.110 |
Why?
| | Respiratory Function Tests | 3 | 2025 | 543 | 0.110 |
Why?
| | Sensitivity and Specificity | 3 | 2018 | 1992 | 0.110 |
Why?
| | Receptors, CXCR5 | 2 | 2026 | 29 | 0.110 |
Why?
| | Diagnosis, Differential | 3 | 2013 | 1500 | 0.110 |
Why?
| | Idiopathic Pulmonary Fibrosis | 2 | 2019 | 697 | 0.110 |
Why?
| | Mothers | 1 | 2021 | 771 | 0.110 |
Why?
| | Neutrophils | 1 | 2021 | 1132 | 0.110 |
Why?
| | Diet | 2 | 2020 | 1271 | 0.110 |
Why?
| | Peptides | 1 | 2021 | 991 | 0.110 |
Why?
| | Tertiary Prevention | 1 | 2014 | 3 | 0.110 |
Why?
| | Vasodilation | 3 | 2013 | 519 | 0.110 |
Why?
| | Cardiovascular Diseases | 3 | 2017 | 2218 | 0.100 |
Why?
| | Adaptation, Psychological | 1 | 2000 | 718 | 0.100 |
Why?
| | Drug Therapy, Combination | 2 | 2021 | 1034 | 0.100 |
Why?
| | Alcohol Drinking | 1 | 2020 | 847 | 0.100 |
Why?
| | Blood Pressure | 2 | 2017 | 1761 | 0.100 |
Why?
| | Respiratory Mucosa | 1 | 2016 | 323 | 0.090 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2013 | 162 | 0.090 |
Why?
| | Secondary Prevention | 1 | 2014 | 247 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2020 | 942 | 0.090 |
Why?
| | Family Health | 2 | 2013 | 192 | 0.090 |
Why?
| | Asthma | 1 | 2024 | 1800 | 0.090 |
Why?
| | Neoplasms | 2 | 2017 | 2944 | 0.090 |
Why?
| | Porphyromonas gingivalis | 1 | 2012 | 22 | 0.090 |
Why?
| | Bacteroidaceae Infections | 1 | 2012 | 11 | 0.090 |
Why?
| | Primary Prevention | 1 | 2014 | 222 | 0.090 |
Why?
| | Vitamin D | 2 | 2022 | 402 | 0.090 |
Why?
| | Immune Tolerance | 1 | 2014 | 384 | 0.090 |
Why?
| | Periodontitis | 1 | 2012 | 55 | 0.090 |
Why?
| | Communicable Disease Control | 2 | 2024 | 88 | 0.090 |
Why?
| | Health | 1 | 2012 | 81 | 0.090 |
Why?
| | Arthrography | 1 | 2011 | 19 | 0.090 |
Why?
| | Population Surveillance | 1 | 2015 | 477 | 0.090 |
Why?
| | Stress, Psychological | 1 | 2020 | 1169 | 0.090 |
Why?
| | Telomere Shortening | 2 | 2024 | 20 | 0.090 |
Why?
| | Pneumonia, Bacterial | 1 | 2013 | 114 | 0.090 |
Why?
| | Delayed Diagnosis | 1 | 2012 | 102 | 0.090 |
Why?
| | Disease Susceptibility | 3 | 2021 | 339 | 0.080 |
Why?
| | RNA, Messenger | 3 | 2025 | 2783 | 0.080 |
Why?
| | Predictive Value of Tests | 3 | 2013 | 2097 | 0.080 |
Why?
| | Proportional Hazards Models | 3 | 2021 | 1318 | 0.080 |
Why?
| | Logistic Models | 5 | 2020 | 2112 | 0.080 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 96 | 0.080 |
Why?
| | Labor, Induced | 1 | 2011 | 40 | 0.080 |
Why?
| | Phenotype | 4 | 2023 | 3186 | 0.080 |
Why?
| | Breast Neoplasms | 1 | 2023 | 2411 | 0.080 |
Why?
| | Follow-Up Studies | 4 | 2019 | 5397 | 0.080 |
Why?
| | Reproducibility of Results | 3 | 2020 | 3396 | 0.080 |
Why?
| | Cyclophosphamide | 1 | 2011 | 275 | 0.080 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2011 | 134 | 0.080 |
Why?
| | Time-to-Treatment | 1 | 2012 | 257 | 0.080 |
Why?
| | Vasodilator Agents | 1 | 2012 | 326 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 1403 | 0.080 |
Why?
| | Statistics, Nonparametric | 1 | 2010 | 423 | 0.080 |
Why?
| | Air Pollution | 1 | 2013 | 314 | 0.070 |
Why?
| | Colorado | 3 | 2020 | 4588 | 0.070 |
Why?
| | Menopause | 1 | 2012 | 327 | 0.070 |
Why?
| | Respiratory Insufficiency | 1 | 2013 | 330 | 0.070 |
Why?
| | Community-Institutional Relations | 1 | 2009 | 101 | 0.070 |
Why?
| | Interleukin-6 | 3 | 2021 | 782 | 0.070 |
Why?
| | Aging | 1 | 2019 | 1983 | 0.070 |
Why?
| | Odds Ratio | 3 | 2018 | 1070 | 0.070 |
Why?
| | Treatment Outcome | 3 | 2021 | 11744 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 483 | 0.070 |
Why?
| | Prognosis | 3 | 2026 | 4331 | 0.070 |
Why?
| | Alleles | 3 | 2019 | 900 | 0.060 |
Why?
| | Aspirin | 1 | 2011 | 404 | 0.060 |
Why?
| | Colposcopy | 1 | 2007 | 18 | 0.060 |
Why?
| | Disease Outbreaks | 1 | 2010 | 420 | 0.060 |
Why?
| | Brachial Artery | 3 | 2013 | 206 | 0.060 |
Why?
| | Obesity | 1 | 2020 | 3123 | 0.060 |
Why?
| | Societies, Medical | 2 | 2021 | 901 | 0.060 |
Why?
| | Lectins, C-Type | 1 | 2026 | 61 | 0.060 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 2026 | 106 | 0.060 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2006 | 30 | 0.060 |
Why?
| | Stroke | 1 | 2015 | 1283 | 0.060 |
Why?
| | Ultrasonography | 2 | 2025 | 788 | 0.060 |
Why?
| | Zimbabwe | 1 | 2025 | 76 | 0.060 |
Why?
| | Environment | 2 | 2019 | 295 | 0.060 |
Why?
| | Mice | 4 | 2025 | 18266 | 0.050 |
Why?
| | Switzerland | 1 | 2025 | 45 | 0.050 |
Why?
| | Capillaries | 1 | 2005 | 123 | 0.050 |
Why?
| | Premenopause | 2 | 2017 | 129 | 0.050 |
Why?
| | Radiography, Thoracic | 1 | 2005 | 174 | 0.050 |
Why?
| | Healthy Volunteers | 2 | 2017 | 217 | 0.050 |
Why?
| | Bronchoscopy | 1 | 2005 | 227 | 0.050 |
Why?
| | Arthritis, Juvenile | 1 | 2005 | 64 | 0.050 |
Why?
| | Pregnancy | 2 | 2021 | 7217 | 0.050 |
Why?
| | Quarantine | 1 | 2024 | 31 | 0.050 |
Why?
| | Immunity, Mucosal | 2 | 2014 | 97 | 0.050 |
Why?
| | Interleukin-2 | 2 | 2016 | 434 | 0.050 |
Why?
| | Aminosalicylic Acids | 1 | 2023 | 10 | 0.050 |
Why?
| | Antigens, CD | 1 | 2026 | 559 | 0.050 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2023 | 26 | 0.050 |
Why?
| | Pulmonary Alveoli | 1 | 2005 | 385 | 0.050 |
Why?
| | Prevotella | 1 | 2023 | 27 | 0.050 |
Why?
| | Vimentin | 1 | 2023 | 47 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2024 | 8351 | 0.050 |
Why?
| | Antibodies | 1 | 2005 | 395 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 2 | 2025 | 3917 | 0.050 |
Why?
| | Health Policy | 1 | 2025 | 399 | 0.040 |
Why?
| | Biopsy | 1 | 2005 | 1073 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2021 | 1531 | 0.040 |
Why?
| | Employment | 1 | 2024 | 180 | 0.040 |
Why?
| | Immunoglobulins | 2 | 2015 | 162 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2022 | 334 | 0.040 |
Why?
| | Carotid Arteries | 2 | 2013 | 206 | 0.040 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2021 | 35 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2014 | 6050 | 0.040 |
Why?
| | Body Mass Index | 2 | 2020 | 2446 | 0.040 |
Why?
| | Adolescent | 5 | 2025 | 22451 | 0.040 |
Why?
| | Janus Kinase Inhibitors | 1 | 2021 | 27 | 0.040 |
Why?
| | Putrescine | 1 | 2020 | 3 | 0.040 |
Why?
| | Xenobiotics | 1 | 2021 | 30 | 0.040 |
Why?
| | Butyric Acid | 1 | 2020 | 6 | 0.040 |
Why?
| | Genetic Markers | 1 | 2022 | 337 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2005 | 824 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 172 | 0.040 |
Why?
| | Microbiota | 2 | 2021 | 724 | 0.040 |
Why?
| | Caprylates | 1 | 2020 | 21 | 0.040 |
Why?
| | Spermidine | 1 | 2020 | 18 | 0.040 |
Why?
| | Vitamins | 1 | 2022 | 183 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 705 | 0.040 |
Why?
| | Urban Population | 1 | 2024 | 496 | 0.040 |
Why?
| | Docosahexaenoic Acids | 1 | 2021 | 90 | 0.040 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2020 | 2 | 0.040 |
Why?
| | Phosphatidylethanolamines | 1 | 2020 | 78 | 0.040 |
Why?
| | Europe | 1 | 2021 | 420 | 0.040 |
Why?
| | Telomere | 1 | 2024 | 300 | 0.040 |
Why?
| | Chemokine CXCL13 | 1 | 2020 | 15 | 0.040 |
Why?
| | Synovial Fluid | 1 | 2020 | 69 | 0.040 |
Why?
| | Carnitine | 1 | 2020 | 91 | 0.040 |
Why?
| | Chemokine CXCL9 | 1 | 2020 | 38 | 0.040 |
Why?
| | Survival Analysis | 2 | 2017 | 1372 | 0.040 |
Why?
| | Acute-Phase Proteins | 1 | 2020 | 66 | 0.040 |
Why?
| | Chemokine CXCL10 | 1 | 2020 | 39 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2024 | 1160 | 0.040 |
Why?
| | Interleukin-8 | 1 | 2021 | 268 | 0.040 |
Why?
| | Child Health | 1 | 2021 | 152 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 2020 | 345 | 0.040 |
Why?
| | Interleukin-1alpha | 1 | 2020 | 55 | 0.040 |
Why?
| | Methionine | 1 | 2020 | 160 | 0.040 |
Why?
| | RNA, Viral | 1 | 2024 | 691 | 0.040 |
Why?
| | Ontario | 1 | 2000 | 91 | 0.040 |
Why?
| | Antibody Specificity | 1 | 2020 | 181 | 0.040 |
Why?
| | Interinstitutional Relations | 1 | 2000 | 56 | 0.040 |
Why?
| | Anxiety | 1 | 2007 | 1118 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2010 | 4565 | 0.040 |
Why?
| | Baltimore | 1 | 2019 | 71 | 0.040 |
Why?
| | International Cooperation | 1 | 2020 | 192 | 0.040 |
Why?
| | Tryptophan | 1 | 2020 | 183 | 0.040 |
Why?
| | Endotoxins | 1 | 2020 | 215 | 0.040 |
Why?
| | Consensus | 1 | 2021 | 465 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2023 | 676 | 0.040 |
Why?
| | Interleukin-1beta | 1 | 2021 | 394 | 0.040 |
Why?
| | Genotype | 2 | 2018 | 1866 | 0.040 |
Why?
| | Interferons | 1 | 2020 | 186 | 0.040 |
Why?
| | Rural Population | 1 | 2024 | 673 | 0.030 |
Why?
| | Interleukins | 1 | 2020 | 247 | 0.030 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2018 | 20 | 0.030 |
Why?
| | Dysbiosis | 1 | 2020 | 184 | 0.030 |
Why?
| | Nurses | 1 | 2020 | 171 | 0.030 |
Why?
| | Forecasting | 1 | 2020 | 386 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2021 | 610 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2025 | 3121 | 0.030 |
Why?
| | Gene Frequency | 1 | 2019 | 495 | 0.030 |
Why?
| | Antibodies, Viral | 1 | 2022 | 683 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 319 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2019 | 2228 | 0.030 |
Why?
| | Genetic Testing | 1 | 2020 | 491 | 0.030 |
Why?
| | Child | 4 | 2025 | 22638 | 0.030 |
Why?
| | Goserelin | 1 | 2017 | 8 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2020 | 495 | 0.030 |
Why?
| | Fertility Agents, Female | 1 | 2017 | 23 | 0.030 |
Why?
| | Bacteria | 1 | 2023 | 766 | 0.030 |
Why?
| | Raloxifene Hydrochloride | 1 | 2017 | 15 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2024 | 1334 | 0.030 |
Why?
| | Phylogeny | 1 | 2021 | 921 | 0.030 |
Why?
| | Leuprolide | 1 | 2017 | 21 | 0.030 |
Why?
| | Amino Acids | 1 | 2021 | 513 | 0.030 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2017 | 33 | 0.030 |
Why?
| | Genes, Immunoglobulin Light Chain | 1 | 2016 | 4 | 0.030 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2016 | 10 | 0.030 |
Why?
| | Phosphofructokinase-2 | 1 | 2016 | 16 | 0.030 |
Why?
| | Estrogens, Conjugated (USP) | 1 | 2017 | 52 | 0.030 |
Why?
| | Decision Support Techniques | 1 | 2021 | 473 | 0.030 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 69 | 0.030 |
Why?
| | Aromatase Inhibitors | 1 | 2017 | 81 | 0.030 |
Why?
| | Protective Factors | 1 | 2016 | 97 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2020 | 728 | 0.030 |
Why?
| | Models, Statistical | 1 | 2020 | 667 | 0.030 |
Why?
| | Health Education | 1 | 2018 | 346 | 0.030 |
Why?
| | Androgens | 1 | 2017 | 179 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2000 | 698 | 0.030 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2017 | 215 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1511 | 0.030 |
Why?
| | Symptom Assessment | 1 | 2016 | 137 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2015 | 319 | 0.030 |
Why?
| | Hypercholesterolemia | 1 | 2015 | 95 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 1066 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1236 | 0.030 |
Why?
| | Child, Preschool | 2 | 2025 | 11888 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 771 | 0.020 |
Why?
| | Etanercept | 1 | 2013 | 60 | 0.020 |
Why?
| | HLA-DRB1 Chains | 1 | 2014 | 109 | 0.020 |
Why?
| | Motivation | 1 | 2018 | 601 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2016 | 538 | 0.020 |
Why?
| | Pneumocystis carinii | 1 | 2013 | 12 | 0.020 |
Why?
| | Geographic Information Systems | 1 | 2013 | 45 | 0.020 |
Why?
| | Testosterone | 1 | 2017 | 419 | 0.020 |
Why?
| | Oral Health | 1 | 2014 | 139 | 0.020 |
Why?
| | Interleukin-9 | 1 | 2012 | 12 | 0.020 |
Why?
| | Cell Membrane | 1 | 2016 | 701 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1652 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2013 | 302 | 0.020 |
Why?
| | Communication | 1 | 2018 | 979 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2016 | 586 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2014 | 244 | 0.020 |
Why?
| | Life Style | 1 | 2014 | 495 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 158 | 0.020 |
Why?
| | Connective Tissue Diseases | 1 | 2012 | 85 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2014 | 1030 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 4082 | 0.020 |
Why?
| | Environmental Monitoring | 1 | 2013 | 346 | 0.020 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 344 | 0.020 |
Why?
| | Erythrocytes | 1 | 2016 | 749 | 0.020 |
Why?
| | Particulate Matter | 1 | 2013 | 328 | 0.020 |
Why?
| | Internet | 1 | 2014 | 656 | 0.020 |
Why?
| | Body Composition | 1 | 2013 | 686 | 0.020 |
Why?
| | Overweight | 1 | 2014 | 613 | 0.020 |
Why?
| | Exercise | 1 | 2021 | 2206 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2012 | 780 | 0.020 |
Why?
| | Self Report | 1 | 2013 | 869 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2591 | 0.020 |
Why?
| | Bottle Feeding | 1 | 2007 | 19 | 0.020 |
Why?
| | Histocompatibility Testing | 1 | 2007 | 122 | 0.020 |
Why?
| | Hypertension | 1 | 2015 | 1270 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2015 | 1101 | 0.020 |
Why?
| | Algorithms | 1 | 2014 | 1843 | 0.020 |
Why?
| | Veterans | 1 | 2018 | 1647 | 0.010 |
Why?
| | Tobacco Smoke Pollution | 1 | 2007 | 227 | 0.010 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2007 | 269 | 0.010 |
Why?
| | Siblings | 1 | 2005 | 196 | 0.010 |
Why?
| | Pain | 1 | 2007 | 787 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2007 | 1754 | 0.010 |
Why?
| | Arthritis, Infectious | 1 | 1994 | 77 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2006 | 3930 | 0.000 |
Why?
|
|
Deane's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|